This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More
by Zacks Equity Research
Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
by Zacks Equity Research
The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.
Axsome (AXSM) Up 27.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
by Zacks Equity Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi
by Zacks Equity Research
Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.
Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.
Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More
by Kinjel Shah
Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.
Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
by Zacks Equity Research
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.